WAYNE, Pa., April 21, 2016 /PRNewswire/ -- Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today two upcoming prescription drug take-back days to provide a safe, convenient and responsible means of disposing of prescription drugs.
As a member of the Partners for Success Coalition, a group that works closely with the Pennsylvania Heroin Task Force, Egalet encourages the community to attend the 2nd Annual Community Day this Saturday, April 23 from 11 a.m. to 3 p.m. at Rose Tree Park in Media, PA. The public is invited to attend the free family event which will feature live music, food, raffles and giveaways, community resources, and interactive and educational activities for all ages in addition to an opportunity to dispose of unused, unwanted and expired prescription medications.
According to the Centers for Disease Control and Prevention (CDC), 78 people die every day in America due to prescription drug overdose. In Delaware County alone, fatal overdoses in 2015 and so far in 2016 have accounted for more than 330 deaths. Medicines that languish in home cabinets are highly susceptible to diversion, misuse and abuse. Studies show that approximately 70% of abused prescription drugs are obtained from family and friends.
Police departments across the country are teaming up with the Drug Enforcement Administration (DEA) to allow the community to dispose of expired, unused and unwanted prescription drugs. The efforts are aimed at reducing theft of prescription drugs by ridding residents of their unused medications. In its ten previous Take Back events, DEA and its partners have taken in over five and a half million pounds—more than 2,750 tons—of pills. The DEA will accept medications for disposal to a number of sites Saturday, April 30 from 10 a.m. to 2 p.m. For more information and a complete list of participating drop off locations, please visit http://www.deadiversion.usdoj.gov/drug_disposal/takeback/.
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has two approved products: OXAYDO™ (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using its proprietary Guardian™ Technology, Egalet is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO ER®, formerly known as Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are being developed for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, including the boxed warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.
E. Blair Clark-Schoeb
Senior Vice President, Communications
SOURCE Egalet Corporation